ESR2 and neoplasm: A pilot clinical study further suggests that tumor patients with ERβ >60% experience longer overall survival with gefitinib + fulvestrant than those with ERβ-low tumors (65.5 vs. 21 weeks), highlighting ERβ as a predictive biomarker for endocrine-targeted combinations [66].